CL2011002531A1 - Uso de 7-(2,5-dihidro-4-imidazo[1,2-a]piridina-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil carbonil)-pirrolo[3,2,1-jk][1,4]benzodiazepina para tratar diferentes tipos de leucemia mll y un trastorno mieloproliferativo cronico no mll. - Google Patents
Uso de 7-(2,5-dihidro-4-imidazo[1,2-a]piridina-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil carbonil)-pirrolo[3,2,1-jk][1,4]benzodiazepina para tratar diferentes tipos de leucemia mll y un trastorno mieloproliferativo cronico no mll.Info
- Publication number
- CL2011002531A1 CL2011002531A1 CL2011002531A CL2011002531A CL2011002531A1 CL 2011002531 A1 CL2011002531 A1 CL 2011002531A1 CL 2011002531 A CL2011002531 A CL 2011002531A CL 2011002531 A CL2011002531 A CL 2011002531A CL 2011002531 A1 CL2011002531 A1 CL 2011002531A1
- Authority
- CL
- Chile
- Prior art keywords
- mll
- leukemia
- benzodiazepine
- pyrrol
- pyrrolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16909409P | 2009-04-14 | 2009-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002531A1 true CL2011002531A1 (es) | 2012-06-01 |
Family
ID=42174602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002531A CL2011002531A1 (es) | 2009-04-14 | 2011-10-12 | Uso de 7-(2,5-dihidro-4-imidazo[1,2-a]piridina-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil carbonil)-pirrolo[3,2,1-jk][1,4]benzodiazepina para tratar diferentes tipos de leucemia mll y un trastorno mieloproliferativo cronico no mll. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8802668B2 (enExample) |
| EP (1) | EP2419106A1 (enExample) |
| JP (1) | JP5699129B2 (enExample) |
| KR (1) | KR101290509B1 (enExample) |
| CN (1) | CN102395372B (enExample) |
| AU (1) | AU2010236747B2 (enExample) |
| BR (1) | BRPI1013774A2 (enExample) |
| CA (1) | CA2758473C (enExample) |
| CL (1) | CL2011002531A1 (enExample) |
| DO (1) | DOP2011000312A (enExample) |
| EA (1) | EA018933B1 (enExample) |
| EC (1) | ECSP11011403A (enExample) |
| IL (1) | IL215107A0 (enExample) |
| MA (1) | MA33184B1 (enExample) |
| MX (1) | MX2011010937A (enExample) |
| MY (1) | MY157218A (enExample) |
| NZ (1) | NZ595413A (enExample) |
| PE (1) | PE20120772A1 (enExample) |
| SG (1) | SG175207A1 (enExample) |
| TN (1) | TN2011000500A1 (enExample) |
| TW (1) | TWI453022B (enExample) |
| UA (1) | UA103792C2 (enExample) |
| WO (1) | WO2010120614A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175207A1 (en) | 2009-04-14 | 2011-11-28 | Lilly Co Eli | Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
| US9446048B2 (en) | 2011-03-17 | 2016-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Gsk3抑制劑與抗dr5抗體之組合 |
| CN102887896B (zh) * | 2012-10-26 | 2015-11-18 | 南京工业大学 | 一种2-(咪唑并[1,2-a]吡啶-3-基)乙腈的制备方法 |
| CA2892927A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人t細胞白血病治療薬 |
| CN104945436B (zh) * | 2015-07-09 | 2017-02-08 | 山东罗欣药业集团股份有限公司 | 一种米诺膦酸的制备方法 |
| KR101694063B1 (ko) | 2015-10-12 | 2017-01-17 | 전남대학교병원 | Bio 화합물을 함유하는 심혈관질환의 치료용 조성물 |
| US11071720B2 (en) | 2016-11-03 | 2021-07-27 | Ucl Business Ltd | Cancer therapy |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| CN1312154C (zh) * | 2002-03-05 | 2007-04-25 | 伊莱利利公司 | 作为激酶抑制剂的嘌呤衍生物 |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| AU2008333215B2 (en) | 2007-12-05 | 2013-06-13 | Johannes Gutenberg-Universitat Mainz | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| SG175207A1 (en) * | 2009-04-14 | 2011-11-28 | Lilly Co Eli | Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
-
2010
- 2010-04-08 SG SG2011074705A patent/SG175207A1/en unknown
- 2010-04-08 MY MYPI2011004899A patent/MY157218A/en unknown
- 2010-04-08 CN CN201080016621.9A patent/CN102395372B/zh not_active Expired - Fee Related
- 2010-04-08 CA CA2758473A patent/CA2758473C/en not_active Expired - Fee Related
- 2010-04-08 MX MX2011010937A patent/MX2011010937A/es active IP Right Grant
- 2010-04-08 MA MA34234A patent/MA33184B1/fr unknown
- 2010-04-08 KR KR1020117024044A patent/KR101290509B1/ko not_active Expired - Fee Related
- 2010-04-08 NZ NZ595413A patent/NZ595413A/xx not_active IP Right Cessation
- 2010-04-08 BR BRPI1013774A patent/BRPI1013774A2/pt not_active IP Right Cessation
- 2010-04-08 JP JP2012506078A patent/JP5699129B2/ja not_active Expired - Fee Related
- 2010-04-08 EP EP10714407A patent/EP2419106A1/en not_active Withdrawn
- 2010-04-08 PE PE2011001780A patent/PE20120772A1/es not_active Application Discontinuation
- 2010-04-08 WO PCT/US2010/030315 patent/WO2010120614A1/en not_active Ceased
- 2010-04-08 US US12/756,213 patent/US8802668B2/en not_active Expired - Fee Related
- 2010-04-08 UA UAA201111273A patent/UA103792C2/uk unknown
- 2010-04-08 AU AU2010236747A patent/AU2010236747B2/en not_active Ceased
- 2010-04-08 EA EA201171243A patent/EA018933B1/ru not_active IP Right Cessation
- 2010-04-14 TW TW099111650A patent/TWI453022B/zh not_active IP Right Cessation
-
2011
- 2011-08-14 EC EC2011011403A patent/ECSP11011403A/es unknown
- 2011-09-12 IL IL215107A patent/IL215107A0/en unknown
- 2011-10-04 TN TNP2011000500A patent/TN2011000500A1/en unknown
- 2011-10-11 DO DO2011000312A patent/DOP2011000312A/es unknown
- 2011-10-12 CL CL2011002531A patent/CL2011002531A1/es unknown
-
2014
- 2014-04-30 US US14/265,844 patent/US9044487B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010120614A1 (en) | 2010-10-21 |
| CN102395372A (zh) | 2012-03-28 |
| EP2419106A1 (en) | 2012-02-22 |
| US8802668B2 (en) | 2014-08-12 |
| NZ595413A (en) | 2013-05-31 |
| AU2010236747A1 (en) | 2011-10-06 |
| IL215107A0 (en) | 2011-12-29 |
| CA2758473C (en) | 2013-12-17 |
| BRPI1013774A2 (pt) | 2016-04-05 |
| SG175207A1 (en) | 2011-11-28 |
| EA201171243A1 (ru) | 2012-03-30 |
| MA33184B1 (fr) | 2012-04-02 |
| TW201105328A (en) | 2011-02-16 |
| DOP2011000312A (es) | 2011-10-31 |
| MY157218A (en) | 2016-05-13 |
| JP5699129B2 (ja) | 2015-04-08 |
| KR20120004447A (ko) | 2012-01-12 |
| AU2010236747B2 (en) | 2012-11-08 |
| TN2011000500A1 (en) | 2013-05-24 |
| KR101290509B1 (ko) | 2013-07-26 |
| US9044487B2 (en) | 2015-06-02 |
| CA2758473A1 (en) | 2010-10-21 |
| JP2012524089A (ja) | 2012-10-11 |
| CN102395372B (zh) | 2014-07-02 |
| UA103792C2 (uk) | 2013-11-25 |
| EA018933B1 (ru) | 2013-11-29 |
| ECSP11011403A (es) | 2011-11-30 |
| PE20120772A1 (es) | 2012-06-27 |
| US20140235621A1 (en) | 2014-08-21 |
| TWI453022B (zh) | 2014-09-21 |
| MX2011010937A (es) | 2011-11-02 |
| US20100261712A1 (en) | 2010-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002531A1 (es) | Uso de 7-(2,5-dihidro-4-imidazo[1,2-a]piridina-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil carbonil)-pirrolo[3,2,1-jk][1,4]benzodiazepina para tratar diferentes tipos de leucemia mll y un trastorno mieloproliferativo cronico no mll. | |
| HRP20160683T2 (hr) | Derivati 1-heterociklil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona i njihova uporaba kao modulatori za pde9a | |
| ME03470B (me) | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo [1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u liječenju kancera | |
| AP2011005819A0 (en) | 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators. | |
| ZA201201397B (en) | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | |
| ZA201307296B (en) | 8-ethyl-6-(aryl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer | |
| CL2008001862A1 (es) | Forma cristalina i, iii e hidratada de 6-{difluoro-[6-(1-metil-1h-pirazol-4-il)[1,2,4]triazolo[4,3-b]piridazin-3-il]metil}quinolina; composicion farmaceutica que las comprende; y su uso para prevenir o tratar un un trastorno proliferativo celular. | |
| MX2009002995A (es) | Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico. | |
| ZA201800485B (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| SMT202100607T1 (it) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso dello stesso in politerapia | |
| PT2448940E (pt) | Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica | |
| CL2011002812A1 (es) | Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata. | |
| ZA201000581B (en) | 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof | |
| ZA201209071B (en) | 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof | |
| AP4012A (en) | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES | |
| IL236808B (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| SG11201508653QA (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
| AU317163S (en) | Toilet system for recreational vehicle | |
| AU311402S (en) | Nebuliser |